Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 07, 2024

Glucagon Secretion and Its Association With Glycaemic Control and Ketogenesis During SGLT2 Inhibition by Ipragliflozin in People With Type 1 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study
Diabetes Obes Metab 2024 Jan 22;[EPub Ahead of Print], Y Nakamura, I Horie, T Kitamura, Y Kusunoki, K Nishida, A Yamamoto, Y Hirota, T Fukui, Y Maeda, M Minami, T Matsui, A Kawakami, N Abiru

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading